P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl α-ketoamide based HCV protease inhibitors
Authors:
- Jason LamarJLJason Lamar
- Nancy SnyderNSNancy Snyder
- Yvonne YipYYYvonne Yip
- Deqi GuoDGDeqi Guo
- Nathan YumibeNYNathan Yumibe
- Robert B. JohnsonRJRobert B. Johnson
- Q.MAy WangQWQ.MAy Wang
- John I. GlassJohn I. Glass
- Shu-Hui ChenSCShu-Hui Chen
- 1 January 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (1) , 257-261
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Glycine α-Ketoamides as HCV NS3 Protease InhibitorsBioorganic & Medicinal Chemistry Letters, 2003
- Eli Lilly pays for customer privacy betrayalComputer Fraud and Security, 2002
- Emerging therapies for hepatitis C virus infectionExpert Opinion on Emerging Drugs, 2001
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- Novel Approaches to the Treatment of Hepatitis C Virus InfectionAntiviral Chemistry and Chemotherapy, 2000
- The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3–4A ProteinaseAntiviral Chemistry and Chemotherapy, 1999
- Hepatitis C virus NS3/4A proteaseAntiviral Research, 1998
- Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage ProductsBiochemistry, 1998
- Molecular Targets in Inhibition of Hepatitis C Virus ReplicationAntiviral Chemistry and Chemotherapy, 1997